Janux Therapeutics, Inc. (JANX)
| Market Cap | 874.92M |
| Revenue (ttm) | 7.38M |
| Net Income (ttm) | -60.41M |
| Shares Out | 41.66M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,618 |
| Open | 21.38 |
| Previous Close | 21.84 |
| Day's Range | 20.88 - 22.41 |
| 52-Week Range | 9.39 - 23.64 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.26 (+44.1%) |
| Earnings Date | Mar 17, 2023 |
About JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programm... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for JANX stock is "Buy." The 12-month stock price forecast is $30.26, which is an increase of 44.10% from the latest price.
News
Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Janux Therapeutics, Inc. (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...
Here's Why Janux Therapeutics, Inc. (JANX) Looks Ripe for Bottom Fishing
After losing some value lately, a hammer chart pattern has been formed for Janux Therapeutics, Inc. (JANX), indicating that the stock has found support. This, combined with an upward trend in earnings...
Janux Therapeutics to Present at Upcoming Investor Conferences in November
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...
7 Short-Squeeze Stocks for Bold Contrarians to Consider
Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's vers...
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
7 Short-Squeeze Stocks to Buy for Contrarian Investors
Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a ...
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...
Janux Therapeutics Appoints Winston Kung to Board of Directors
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...
Janux Therapeutics Reports Second Quarter 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today ...